Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hightide Therapeutics Inc ( (HK:2511) ) has provided an update.
HighTide Therapeutics, Inc. has announced a board meeting scheduled for March 28, 2025, to discuss and approve the audited annual results for the year ending December 31, 2024. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and future strategies.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapies for metabolic and digestive diseases.
YTD Price Performance: -13.39%
Average Trading Volume: 615,853
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$545.7M
For an in-depth examination of 2511 stock, go to TipRanks’ Stock Analysis page.